SEI Medical PCL

SEI Medical PCL's capital structure and liquidity position is partially obscured due to the absence of balance-sheet inputs and no going-concern language in the source documents, preventing a full liquidity risk assessment. However, the company reported a free cash flow of 5.63 million THB in the latest period, indicating some capacity to fund operations and capital expenditures. The operating cash flow was negative at -9.45 million THB, suggesting potential challenges in converting revenue into cash from operations.

Profitability metrics show a gross profit of 25.20 million THB and an operating income of 6.49 million THB, translating to a gross margin of approximately 33.45% and an operating margin of 8.61%. These figures are to be compared against the industry_config preferred metrics for the Medical Equipment, Supplies & Distribution sector, which typically emphasize gross margin efficiency and operating leverage. The net income of 4.38 million THB indicates a healthy bottom-line performance, though the absence of cohort medians prevents a direct industry comparison.

The company's revenue is concentrated in a single business segment, as disclosed in the latest financial data, with no geographic breakdown provided. This lack of segmentation detail limits the ability to assess geographic exposure or diversification risk. The absence of competitor share data also prevents a market share analysis.

Growth trajectory is difficult to assess due to the absence of historical revenue data in the input. However, the capital expenditure of -1.997 million THB suggests some investment in infrastructure or equipment, which could support future growth. The outlook for the current fiscal year is not provided, but the company's operating performance and cash flow dynamics suggest a need for close monitoring of future capital deployment and revenue generation.

Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. The dilution risk is currently low, with no evidence of dilution potential in the basic shares outstanding. However, the lack of detailed capital structure data limits the ability to fully evaluate dilution risk.

Recent events and filings are not detailed in the input data, so no specific recent developments can be cited. The company's financial disclosures are limited to the latest period, with no additional context from transcripts or regulatory filings.